**Question:** A 34-year-old woman has Raynaud's phenomenon associated with systemic sclerosis (scleroderma). Which of the following is the most appropriate management for this condition?

A. Corticosteroids
B. Calcium channel blockers
C. Antifibrotic agents
D. Vasodilators

**Correct Answer:** D. Vasodilators

**Core Concept:** Raynaud's phenomenon is a condition characterized by episodes of vasospasm in the extremities, leading to white and blue discoloration followed by pain and numbness. It is commonly associated with systemic sclerosis (scleroderma), a connective tissue disorder characterized by excessive collagen deposition and fibrosis.

**Why the Correct Answer is Right:** In Raynaud's phenomenon, the treatment goal is to dilate the blood vessels to counteract the vasospasm. Vasodilators, such as calcium channel blockers (option B) and nitrates (option D), are medications that directly relax blood vessels by inhibiting calcium influx into smooth muscle cells and increasing nitric oxide production, respectively. These agents can effectively improve blood flow and alleviate symptoms in Raynaud's phenomenon.

**Why Each Wrong Option is Incorrect:**

A. Corticosteroids (option A) are primarily used to treat inflammatory conditions and do not directly address the vasospastic component of Raynaud's phenomenon.

C. Antifibrotic agents (option C) are primarily used for treating fibrosis and excessive collagen deposition, not vasospasm.

**Clinical Pearl:** While systemic sclerosis itself is managed with corticosteroids, antifibrotic agents, and immunosuppressants, the treatment of Raynaud's phenomenon is primarily focused on vasodilation, making vasodilators the most appropriate choice.